Clinical Trial: Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Immunotherapy
Study Type: INTERVENTIONAL
Official Title: A Single-arm Multicenter Phase II Clinical Trial of Cadunilumab (Anti-PD-1/CTLA-4) in Combination With or Without Chemotherapy in Second-line Treatment for Patients With Extensive Stage Small Cel
Brief Summary:
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
Read more